Top

Published in:

01-12-2016 | Gastrointestinal Oncology

Quality-of-Life Evaluation After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy

Authors: Rebecca M. Dodson, MD, Richard P. McQuellon, PhD, Harveshp D. Mogal, MD, Katharine E. Duckworth, PhD, Gregory B. Russell, MS, Konstantinos I. Votanopoulos, MD, PhD, Perry Shen, MD, Edward A. Levine, MD

Published in: Annals of Surgical Oncology | Special Issue 5/2016

Abstract

Background

Cytoreductive surgery (CS) with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastases can alleviate symptoms and prolong survival at the expense of morbidity and quality of life (QoL). This study aimed to monitor QoL and outcomes before and after HIPEC.

Methods

A prospective QoL trial of patients who underwent HIPEC for peritoneal metastases from 2000 to 2015 was conducted. The patients completed the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36), the Functional Assessment of Cancer Therapy + Colon Subscale (FACT-C), the Brief Pain Inventory, the Center for Epidemiologic Studies Depression scale, and the Eastern Cooperative Oncology Group (ECOG) performance status at baseline, then 3, 6, 12, and 24 months after HIPEC. The trial outcome index (TOI) was analyzed. Proportional hazards modeled the effect of baseline QoL on survival.

Results

The 598 patients (53.8 % female) in the study had a mean age of 53.3 years. The overall 1-year survival rate was 76.8 %, and the median survival period was 2.9 years. The findings showed a minor morbidity rate of 29.3 %, a major morbidity rate of 21.7 %, and a 30-day mortality rate of 3.5 %. The BPI (p < 0.0001) and worst pain (p = 0.004) increased at 3 months but returned to baseline at 6 months. After CS + HIPEC, FACT-C emotional well-being, SF-36 mental component score, and emotional health improved (all p < 0.001). Higher baseline FACT-General (hazard ratio [HR], 0.92; 95 % confidence interval [CI], 0.09–0.96), FACT-C (HR, 0.73; 95 % CI 0.65–0.83), physical well-being (HR, 0.71; 95 % CI 0.64–0.78), TOI (HR, 0.87; 95 % CI 0.84–0.91), and SF-36 vitality (HR, 0.88; 95 % CI 0.83–0.92) were associated with improved survival (all p < 0.001). Higher baseline BPI (HR, 1.1; 95 % CI 1.05–1.14; p < 0.0001), worst pain (HR, 1.06; 95 % CI 1.01–1.10; p = 0.01), and ECOG (HR, 1.74; 95 % CI 1.50–2.01; p < 0.0001) were associated with worse survival.

Conclusions

Although HIPEC is associated with morbidity and detriments to QoL, recovery with good overall QoL typically occurs at or before 6 months. Baseline QoL is associated with morbidity, mortality, and survival after HIPEC.

Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34–43. doi:10.1056/NEJMoa052985.CrossRefPubMed

Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21:3737–43. doi:10.1200/JCO.2003.04.187.CrossRefPubMed

Glehen O, Schreiber V, Cotte E, et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer. Arch Surg. 2004;139:20–6. doi:10.1001/archsurg.139.1.20.CrossRefPubMed

Stewart JH IV, Shen P, Russell GB, et al. Appendiceal neoplasms with peritoneal dissemination: outcomes after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy. Ann Surg Oncol. 2006;13:624–34. doi:10.1007/s10434-006-9708-2.CrossRefPubMed

Feldman AL, Libutti SK, Pingpank JF, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol. 2003;21:4560–7. doi:10.1200/JCO.2003.04.150.CrossRefPubMed

Rossi CR, Deraco M, De Simone M, et al. Hyperthermic intraperitoneal intraoperative chemotherapy after cytoreductive surgery for the treatment of abdominal sarcomatosis: clinical outcome and prognostic factors in 60 consecutive patients. Cancer. 2004;100:1943–50. doi:10.1002/cncr.20192.CrossRefPubMed

Levine EA, Stewart JH IV, Shen P, Russell GB, Loggie BL, Votanopoulos KI. Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1000 patients. J Am Coll Surg. 2014;218:573–85. doi:10.1016/j.jamcollsurg.2013.12.013.CrossRefPubMed

Kusamura S, Younan R, Baratti D, et al. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique. Cancer. 2006;106:1144–53. doi:10.1002/cncr.21708.CrossRefPubMed

Smeenk RM, Verwaal VJ, Zoetmulder FAN. Toxicity and mortality of cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei: a report of 103 procedures. Eur J Surg Oncol. 2006;32:186–90. doi:10.1016/j.ejso.2005.08.009.CrossRefPubMed

10.

Shen P, Hawksworth J, Lovato J, et al. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. Ann Surg Oncol. 2004;11:178–86. doi:10.1245/ASO.2004.05.009.CrossRefPubMed

11.

Glehen O, Osinsky D, Cotte E, et al. Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol. 2003;10:863–9. doi:10.1245/ASO.2003.01.018.CrossRefPubMed

12.

McQuellon RP, Loggie BW, Lehman AB, et al. Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol. 2003;10:155–62. doi:10.1245/ASO.2003.03.067.CrossRefPubMed

13.

Levine EA, Stewart JH, Russell GB, Geisinger KR, Loggie BL, Shen P. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: experience with 501 procedures. J Am Coll Surg. 2007;204:943–5.CrossRefPubMed

14.

Stewart JH, Shen P, Levine E. Intraperitoneal hyperthermic chemotherapy: an evolving paradigm for the treatment of peritoneal surface malignancies. Expert Rev Anticancer Ther. 2008;8:1809–18. doi:10.1586/14737140.8.11.1809.PubMed

15.

Beaujard C, Glehen O, Caillot JL, et al. Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis. Cancer. 2000;88:2512–9. http://www.ncbi.nlm.nih.gov/pubmed/10861427.

16.

Chu DZ, Lang NP, Thompson C, Osteen PK, Westbrook KC. Peritoneal carcinomatosis in nongynecologic malignancy: a prospective study of prognostic factors. Cancer. 1989;63:364–7.CrossRefPubMed

17.

Tuttle TM, Zhang Y, Greeno E, Knutsen A. Toxicity and quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2006;13:1627–32. doi:10.1245/s10434-006-9186-6.CrossRefPubMed

18.

Verwaal VJ, Van Tinteren H, Ruth SV, Zoetmulder FN. Toxicity of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Surg Oncol. 2004;85:61–7. doi:10.1002/jso.20013.CrossRefPubMed

19.

Witkamp AJ, De Bree E, Kaag MM, et al. Extensive cytoreductive surgery followed by intraoperative hyperthermic intraperitoneal chemotherapy with mitomycin C in patients with peritoneal carcinomatosis of colorectal origin. Eur J Cancer. 2001;37:979–84. doi:10.1016/S0959-8049(01)00058-2.CrossRefPubMed

20.

Duckworth KE, McQuellon RP, Russell GB, et al. Patient-rated outcomes and survivorship following cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CS + HIPEC). J Surg Oncol. 2012;106:376–80. doi:10.1002/jso.23089.CrossRefPubMedPubMedCentral

21.

Low CA, Bovbjerg DH, Ahrendt S, et al. Depressive symptoms in patients scheduled for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: prospective associations with morbidity and mortality. J Clin Oncol. 2016;34(11):1217–1222. doi:10.1200/JCO.2015.62.9683.CrossRefPubMed

22.

Cella DF, Bonomi AE. Measuring quality of life: 1995 update. Oncology. 1995;9:47–60.PubMed

23.

Mashele MH, Sumithra JM, Paul LS, James RJ, Jeff AS. A pooled analysis of quality-of-life measures and adverse events data in North Central Cancer Treatment Group lung cancer clinical trials. Cancer 2007;109:787–95. http://search.ebscohost.com/login.aspx?direct=true&db=a2h&AN=25518368&site=ehost-live&scope=site.

24.

Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11:570–9. http://www.ncbi.nlm.nih.gov/pubmed/8445433.

25.

Earlam S, Glover C, Fordy C, Burke D, Allen-Mersh TG. Relation between tumor size, quality of life, and survival in patients with colorectal liver metastases. J Clin Oncol. 1996;14:171–5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8558193.

26.

Saxton A, Velanovich V. Preoperative frailty and quality of life as predictors of postoperative complications. Ann Surg. 2011;253:1223–9. doi:10.1097/SLA.0b013e318214bce7.CrossRefPubMed

27.

Daut RL, Cleeland CS, Flanery RC. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain. 1983;17:197–210. doi:10.1016/0304-3959(83)90143-4.CrossRefPubMed

28.

Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1:385–401. doi:10.1177/014662167700100306.CrossRef

29.

Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–56. doi:10.1097/00000421-198212000-00014.CrossRefPubMed

30.

Dindo D, Demartines N, Clavien P-A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13. doi:10.1097/01.sla.0000133083.54934.ae.CrossRefPubMedPubMedCentral

31.

Mcquellon R, Gavazzi C, Piso P, Swain D, Levine E. Quality of life and nutritional assessment in peritoneal surface malignancy (PSM): recommendations for care. J Surg Oncol. 2008;98:300–95. doi:10.1002/jso.21050.CrossRefPubMed

32.

Anthony T, Hynan LS, Rosen D, et al. The association of pretreatment health-related quality of life with surgical complications for patients undergoing open surgical resection for colorectal cancer. Ann Surg. 2003;238:690–6. doi:10.1097/01.sla.0000094304.17672.6e.CrossRefPubMedPubMedCentral

33.

Britton B, Clover K, Bateman L, et al. Baseline depression predicts malnutrition in head and neck cancer patients undergoing radiotherapy. Support Care Cancer. 2012;20:335–42. doi:10.1007/s00520-011-1087-y.CrossRefPubMed

34.

Ihemelandu CU, McQuellon R, Shen P, Stewart JH, Votanopoulos K, Levine EA. Predicting postoperative morbidity following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CS + HIPEC) with preoperative FACT-C (Functional Assessment of Cancer Therapy) and patient-rated performance status. Ann Surg Oncol. 2013;20(11):3519–26. doi:10.1245/s10434-013-3049-8.CrossRef

35.

Hill AR, McQuellon RP, Russell GB, Shen P, Stewart JH, Levine EA. Survival and quality of life following cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis of colonic origin. Ann Surg Oncol. 2011;18:3673–9. doi:10.1245/s10434-011-1793-1.CrossRefPubMedPubMedCentral

36.

Trask PC, Hsu MA, McQuellon R. Other paradigms: health-related quality of life as a measure in cancer treatment: its importance and relevance. Cancer J. 2009;15:435–40. doi:10.1097/PPO.0b013e3181b9c5b9.CrossRefPubMed

37.

Reuter NP, MacGregor JM, Woodall CE, et al. Preoperative performance status predicts outcome following heated intraperitoneal chemotherapy. Am J Surg. 2008;196:909–14. doi:10.1016/j.amjsurg.2008.06.037.CrossRefPubMed

38.

Shen P, Levine E, Hall J, et al. Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. Arch Surg. 2003;138:26–33.CrossRefPubMed

39.

Deraco M, Nonaka D, Baratti D, et al. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol. 2006;13:229–37. doi:10.1245/ASO.2006.03.045.CrossRefPubMed

40.

Esquivel J, Sticca R, Sugarbaker P, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Ann Surg Oncol. 2007;14:128–33. doi:10.1245/s10434-007-9599-x.CrossRefPubMed

41.

Giannousi Z, Gioulbasanis I, Pallis AG, et al. Nutritional status, acute phase response, and depression in metastatic lung cancer patients: correlations and association prognosis. Support Care Cancer. 2012;20:1823–9. doi:10.1007/s00520-011-1282-x.CrossRefPubMed

42.

Lazure KE, Lydiatt WM, Denman D, Burke WJ. Association between depression and survival or disease recurrence in patients with head and neck cancer enrolled in a depression prevention trial. Head Neck. 2009;31:888–92. doi:10.1002/hed.21046.CrossRefPubMed

43.

Watson M, Haviland JS, Greer S, Davidson J, Bliss JM. Influence of psychological response on survival in breast cancer: a population-based cohort study. Lancet. 1999;354:1331–6. doi:10.1016/S0140-6736(98)11392-2.CrossRefPubMed

44.

Cunningham AJ, Phillips C, Stephen J, Edmonds C. Fighting for life: a qualitative analysis of the process of psychotherapy-assisted self-help in patients with metastatic cancer. Integr Cancer Ther. 2002;1:146–61. doi:10.1177/1534735402001002006.CrossRefPubMed

45.

Goodwin PJ, Leszcz M, Ennis M, et al. The effect of group psychosocial support on survival in metastatic breast cancer. N Engl J Med. 2001;345:1719–26. doi:10.1056/NEJMoa011871.CrossRefPubMed

46.

Mehanna HM, De Boer MF, Morton RP. The association of psychosocial factors and survival in head and neck cancer. Clin Otolaryngol. 2008;33:83–9. doi:10.1111/j.1749-4486.2008.01666.x.CrossRefPubMed

47.

Fisch MJ, Loehrer PJ, Kristeller J, et al. Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. J Clin Oncol. 2003;21:1937–43. doi:10.1200/JCO.2003.08.025.CrossRefPubMed

48.

Holland JC, Romano SJ, Heiligenstein JH, Tepner RG, Wilson MG. A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer. Psychooncology. 1998;7:291–300. doi:10.1002/(SICI)1099-1611(199807/08)7:4<291::AID-PON361>3.0.CO;2-U.CrossRefPubMed

Title: Quality-of-Life Evaluation After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy
Authors: Rebecca M. Dodson, MD
Richard P. McQuellon, PhD
Harveshp D. Mogal, MD
Katharine E. Duckworth, PhD
Gregory B. Russell, MS
Konstantinos I. Votanopoulos, MD, PhD
Perry Shen, MD
Edward A. Levine, MD
Publication date: 01-12-2016
Publisher: Springer International Publishing
Published in: Annals of Surgical Oncology / Issue Special Issue 5/2016
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-016-5547-y

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Quality-of-Life Evaluation After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Special Issue 5/2016

Breast Cancer Axillary Surgery: Before, After, or None at All?

Outcomes of Rehepatectomy for Colorectal Liver Metastases: A Contemporary Multi-Institutional Analysis from the French Surgical Association Database

PTFE Graft as a “Bridge” to Communicating Veins Maturation in the Treatment of an Intrahepatic Cholangiocarcinoma Involving the 3 Hepatic Veins. The Minor-but-Complex Liver Resection

Distal Pancreatectomy with en Bloc Celiac Axis Resection (Modified Appleby Procedure) for Locally Advanced Pancreatic Body Cancer: A Single-Center Review of 80 Consecutive Patients

Surgeon Volume, Patient Age, and Tumor-Related Factors Influence the Need for Re-Excision After Breast-Conserving Surgery

Antiplatelet Therapy is Associated with a Better Prognosis for Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma after Liver Resection